chr2:29209798:C>T Detail (hg38) (ALK)
Information
Genome
Assembly | Position |
---|---|
hg19 | chr2:29,432,664-29,432,664 View the variant detail on this assembly version. |
hg38 | chr2:29,209,798-29,209,798 |
HGVS
Type | Transcript | Protein |
---|---|---|
RefSeq | NM_004304.4:c.3824G>A | NP_004295.2:p.Arg1275Gln |
Ensemble | ENST00000389048.8:c.3824G>A | ENST00000389048.8:p.Arg1275Gln |
ENST00000618119.4:c.2693G>A | ENST00000618119.4:p.Arg898Gln |
Summary
MGeND
Clinical significance |
![]() ![]() |
Variant entry | 9 |
GWAS entry | |
Disease area statistics | Show details |
Disease area statistics
MGeND
Clinical significance | Last evaluated | Condition | Origin | Submission ID | Submitter | Institute | Citation | Comment | Image |
---|---|---|---|---|---|---|---|---|---|
![]() |
neuroblastoma |
![]() |
MGS000001
(TMGS000154) |
Kenjiro Kosaki | Keio University | ||||
![]() |
other |
![]() |
MGS000001
(TMGS000162) |
Kenjiro Kosaki | Keio University | ||||
![]() |
other |
![]() |
MGS000001
(TMGS000174) |
Kenjiro Kosaki | Keio University | ||||
![]() |
other |
![]() |
MGS000001
(TMGS000174) |
Kenjiro Kosaki | Keio University |
ClinVar
Clinical significance | Last evaluated | Review status | Condition | Origin | Links |
---|---|---|---|---|---|
![]() |
2023-04-19 | criteria provided, multiple submitters, no conflicts | Neuroblastoma, susceptibility to, 3 |
![]() ![]() ![]() |
Detail |
![]() |
2016-05-31 | no assertion criteria provided | Breast neoplasm |
![]() |
Detail |
![]() |
2016-05-31 | no assertion criteria provided | neuroblastoma |
![]() |
Detail |
![]() |
2014-12-26 | no assertion criteria provided | Neoplasm of brain |
![]() |
Detail |
![]() |
2020-10-23 | criteria provided, single submitter | not provided |
![]() |
Detail |
![]() |
2022-04-29 | criteria provided, single submitter | Hereditary cancer-predisposing syndrome |
![]() |
Detail |
CIViC
Disease | Drug | EL | ET | ED | CS | VO | TR | Pubmed | Links |
---|---|---|---|---|---|---|---|---|---|
neuroblastoma | Crizotinib | C |
![]() |
![]() |
Sensitivity/Response | Rare Germline | 2 | 23598171 | Detail |
neuroblastoma | Crizotinib | C |
![]() |
![]() |
Sensitivity/Response | Somatic | 2 | 23598171 | Detail |
neuroblastoma | Lorlatinib | D |
![]() |
![]() |
Sensitivity/Response | Somatic | 4 | 26554404 | Detail |
neuroblastoma | Crizotinib | D |
![]() |
![]() |
Sensitivity/Response | Somatic | 3 | 22072639 | Detail |
neuroblastoma | TAE684 | D |
![]() |
![]() |
Sensitivity/Response | Somatic | 3 | 18923525 | Detail |
neuroblastoma | TAE684 | D |
![]() |
![]() |
Resistance | Somatic | 3 | 18923525 | Detail |
DisGeNET
Score | Disease name | Description | Source | Pubmed | Links |
---|---|---|---|---|---|
0.023 | Central neuroblastoma | Activating mutations within the full-length ALK kinase domain, most commonly R12... | BeFree | 20632993 | Detail |
0.279 | neuroblastoma | Activating mutations within the full-length ALK kinase domain, most commonly R12... | BeFree | 20632993 | Detail |
0.240 | Neuroblastoma, susceptibility to, 3 | NA | CLINVAR | Detail | |
0.080 | Central neuroblastoma | The two most frequent mutations, ALK-F1174L and ALK-R1275Q, contribute to NB tum... | BeFree | 24947326 | Detail |
0.334 | neuroblastoma | The two most frequent mutations, ALK-F1174L and ALK-R1275Q, contribute to NB tum... | BeFree | 24947326 | Detail |
0.010 | Carcinogenesis | The two most frequent mutations, ALK-F1174L and ALK-R1275Q, contribute to NB tum... | BeFree | 24947326 | Detail |
Annotation
Annotations
Descrption | Source | Links |
---|---|---|
This Phase I study of crizotinib involved a cohort of pediatric neuroblastoma patients between ages ... | CIViC Evidence | Detail |
A cohort of pediatric neuroblastoma patients ages 12 months to 22 years were assessed for response t... | CIViC Evidence | Detail |
In NB-1643 and LAN-5 neuroblastoma cell lines containing R1275Q mutation, PF-06463922 showed 51 and ... | CIViC Evidence | Detail |
Cells lines expressing ALK harboring the F1174L mutation are less sensitive to growth inhibition by ... | CIViC Evidence | Detail |
TAE684 inhibits growth of Ba/F3 cells expressing ALK mutations; however, cells with the R1275Q mutat... | CIViC Evidence | Detail |
The SMS-KCNR cell line harboring the R1275Q mutation was resistant to TAE684. | CIViC Evidence | Detail |
NM_004304.5(ALK):c.3824G>A (p.Arg1275Gln) AND Neuroblastoma, susceptibility to, 3 | ClinVar | Detail |
NM_004304.5(ALK):c.3824G>A (p.Arg1275Gln) AND Breast neoplasm | ClinVar | Detail |
NM_004304.5(ALK):c.3824G>A (p.Arg1275Gln) AND Neuroblastoma | ClinVar | Detail |
NM_004304.5(ALK):c.3824G>A (p.Arg1275Gln) AND Neoplasm of brain | ClinVar | Detail |
NM_004304.5(ALK):c.3824G>A (p.Arg1275Gln) AND not provided | ClinVar | Detail |
NM_004304.5(ALK):c.3824G>A (p.Arg1275Gln) AND Hereditary cancer-predisposing syndrome | ClinVar | Detail |
Activating mutations within the full-length ALK kinase domain, most commonly R1275Q and F1174L, whic... | DisGeNET | Detail |
Activating mutations within the full-length ALK kinase domain, most commonly R1275Q and F1174L, whic... | DisGeNET | Detail |
NA | DisGeNET | Detail |
The two most frequent mutations, ALK-F1174L and ALK-R1275Q, contribute to NB tumorigenesis in mouse ... | DisGeNET | Detail |
The two most frequent mutations, ALK-F1174L and ALK-R1275Q, contribute to NB tumorigenesis in mouse ... | DisGeNET | Detail |
The two most frequent mutations, ALK-F1174L and ALK-R1275Q, contribute to NB tumorigenesis in mouse ... | DisGeNET | Detail |
Overlapped Transcript Coordinates
Gene | Transcript ID | Exon Number | Chromosome | Start | Stop | Type | Amino Mutation | Transcript Position | Links |
---|
Overlapped Transcript
Gene | Transcript ID | Chromosome | Start | Stop | Links |
---|
- Gene
- -
- dbSNP
- rs113994087 dbSNP
- Genome
- hg38
- Position
- chr2:29,209,798-29,209,798
- Variant Type
- snv
- Reference Allele
- C
- Alternative Allele
- T
- Variant (CIViC) (CIViC Variant)
- R1275Q
- Transcript 1 (CIViC Variant)
- ENST00000389048.3
- Variant URL (CIViC Variant)
- https://civic.genome.wustl.edu/links/variants/9
- Summary (CIViC Variant)
- ALK R1275Q has been observed as a recurrent mutation in neuroblastoma, non-small cell lung cancer (NSCLC), as well as other cancer types. Neuroblastoma cells with this mutation have shown sensitivity to the ALK-inhibitor TAE684. This and the geldanamycin deriviative 17-DMAG have been shown to be effective in NSCLC cell lines.
Genome browser